secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001567264-25-000104
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics Q3 net loss $2.7M; pauses two trials, extends cash runway to Q1 2027
--------------------------------------------------------------------------------

- Net loss $2.7M for Q3 2025 vs $3.5M YoY; cash $7.1M at Sept 30, plus $6.1M raised in Q4 2025.
- INVINCIBLE-4 study paused; plans protocol amendment in Q1 2026 to revise INT230-6 dosing, restart enrollment Q1 2026.
- INVINCIBLE-3 study paused since March 2025 due to funding constraints; 21 patients enrolled, plan to restart with sufficient funding.
- IT-01 study published in eBioMedicine: 75% disease control rate, 11.9 mo median OS; 20% abscopal effects in >40% tumor burden group.
- Capital raises: $7.5M ATM in Q3, $2.1M ATM in Oct, $4.0M registered direct offering in Oct; cash runway extended to Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/0001567264-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726425000104/intensity-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001567264-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer